These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38141092)

  • 1. Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
    Dos Santos Borges R; de Oliveira Almeida G; Alves VFC; Nienkotter TF; Bertoli ED; Simões E Silva AC
    J Nephrol; 2024 May; 37(4):881-896. PubMed ID: 38141092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
    N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
    Sridhar VS; Bhatt DL; Odutayo A; Szarek M; Davies MJ; Banks P; Pitt B; Steg PG; Cherney DZI
    Clin J Am Soc Nephrol; 2024 May; 19(5):557-564. PubMed ID: 38277468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Kakotrichi P; Michailidis T; Liakos A; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2022 Jan; 24(1):106-114. PubMed ID: 34545668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
    Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
    Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E
    Adv Ther; 2024 Jul; 41(7):2826-2844. PubMed ID: 38771475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
    Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
    Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials.
    Zhou F; Du N; Zhou L; Wang C; Ren H; Sun Q
    Front Endocrinol (Lausanne); 2022; 13():968478. PubMed ID: 36225203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Powell DR; Davies MJ; Banks P; Agarwal R
    Diabetes Obes Metab; 2023 Jun; 25(6):1646-1657. PubMed ID: 36782093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
    Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
    Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
    Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.